The Supportive Treatment of IgA Nephropathy and Idiopathic Nephrotic Syndrome: How Useful are Omega-3 Polyunsaturated Fatty Acids?

References

• Hwang S, Tsai J, Chen H. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology (Carlton). 2010;15(Suppl 2):3–9. doi:10.1111/nep.2010.15.issue-s220586940
   PubMed Web of Science ®Google Scholar
• Chembo CL, Marshall MR, Williams LC, et al. Long-term outcomes for primary glomerulonephritis: New Zealand glomerulonephritis study. Nephrology (Carlton). 2015;20(12):899–907. doi:10.1111/nep.2015.20.issue-1226096749
   PubMed Web of Science ®Google Scholar
• Murugapandian S, Mansour I, Hudeeb M, et al. Epidemiology of glomerular disease in Southern Arizona: a review of 10-year renal biopsy data. Medicine. 2016;95(18):e3633. doi:10.1097/MD.000000000000363327149502
   PubMed Web of Science ®Google Scholar
• D’Amico G. The commonest glomerulonephritis in the world: igA nephropathy. Q J Med. 1987;645:709–727.
   Google Scholar
• Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362:629–639. doi:10.1016/S0140-6736(03)14184-012944064
   PubMed Web of Science ®Google Scholar
• Uwaezuoke SN, Ndu IK, Mbanefo NR. Prevalence rates of histopathologic subtypes associated with steroid resistance in childhood nephrotic syndrome in Sub-Saharan Africa: a systematic review. Int J Nephrol Renovasc Dis. 2019;12:167–176. doi:10.2147/IJNRD.S20737231372025
   PubMed Web of Science ®Google Scholar
• International Study of Kidney Disease in Children. Nephrotic syndrome in children. Prediction of histopathology from clinical and laboratory characteristics at the time of diagnosis. Kidney Int. 1978;13:15–65. doi:10.1038/ki.1978.23101707
   PubMed Web of Science ®Google Scholar
• Gulati S, Sharma AP, Sharma RK, Gupta A. Changing trends of histopathology in childhood nephrotic syndrome. Am J Kidney Dis. 1999;34(4):646–650. doi:10.1016/S0272-6386(99)70388-410516344
   PubMed Web of Science ®Google Scholar
• Downie ML, Gallibois C, Parekh RS, Noone DG. Nephrotic syndrome in infants and children: pathophysiology and management. Paediatr Int Child Health. 2017;37(4):248–258. doi:10.1080/20469047.2017.137400328914167
   PubMed Web of Science ®Google Scholar
• Srivastava T, Simon SD, Alon US. High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol. 1999;13(1):13–18. doi:10.1007/s00467005055510100283
   PubMed Web of Science ®Google Scholar
• Bonilla-Felix M, Parra C, Dajani T, et al. Changing patterns in the histopathology of idiopathic nephrotic syndrome in children. Kidney Int. 1999;55(5):1885–1890. doi:10.1046/j.1523-1755.1999.00408.x10231451
   PubMed Web of Science ®Google Scholar
• Filler G, Young E, Geier P, Carpenter B, Drukker A, Feber J. Is there really an increase in non-minimal change nephrotic syndrome in children? Am J Kidney Dis. 2003;42(6):1107–1113. doi:10.1053/j.ajkd.2003.08.01014655180
   PubMed Web of Science ®Google Scholar
• Penfold RS, Prendecki M, McAdoo S, Tam FWK. Primary IgA nephropathy: current challenges and future prospects. Int J Nephrol Renovasc Dis. 2018;11:137–148. doi:10.2147/IJNRD.S12922729695925
   PubMed Web of Science ®Google Scholar
• KDIGO. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2(2):209–217.
   Web of Science ®Google Scholar
• D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36:227–237. doi:10.1053/ajkd.2000.896610922300
   PubMed Web of Science ®Google Scholar
• Selvaskandan H, Cheung CK, Muto M, Barratt J. New strategies and perspectives on managing IgA nephropathy. Clin Exp Nephrol. 2019;23:577–588. doi:10.1007/s10157-019-01700-130756248
   PubMed Web of Science ®Google Scholar
• Fassett RG, Gobe GC, Peake JM, Coombes JS. Omega-3 polyunsaturated fatty acids in the treatment of kidney disease. Am J Kidney Dis. 2010;56(4):728–742. doi:10.1053/j.ajkd.2010.03.00920493605
   PubMed Web of Science ®Google Scholar
• Clark WF, Parbtani A, Philbrick DJ, Holub BJ, Huff MW. Chronic effects of ω-3 fatty acids (fish oil) in a rat 5/6 ablation model. J Am Soc Nephrol. 1991;1:1343–1353.1912396
   PubMed Web of Science ®Google Scholar
• Hall AV, Parbtani A, Clark WF, et al. Omega-3 fatty acid supplementation in primary nephrotic syndrome: effects on plasma lipids and coagulopathy. J Am Soc Nephrol. 1992;3:1321–1329.1477328
   PubMed Web of Science ®Google Scholar
• Wheeler DC. Lipids - what is the evidence for their role in progressive renal disease? Nephrol Dial Transplant. 1995;10:14–16. doi:10.1093/oxfordjournals.ndt.a090837
   Web of Science ®Google Scholar
• Hirahashi J. Omega-3 polyunsaturated fatty acids for the treatment of IgA nephropathy. J Clin Med. 2017;6(7):E70. doi:10.3390/jcm607007028753924
   PubMed Web of Science ®Google Scholar
• Moriyama T, Kumon S, Kamiyama T, Karasawa K, Uchida K, Nitta K. The renoprotective effects of docosahexaenoic acid as add-on therapy in patients receiving eicosapentaenoic acid as a treatment for IgA nephropathy: a pilot uncontrolled trial. Intern Med. 2018;57(2):173–179. doi:10.2169/internalmedicine.9155-1729093399
   PubMed Web of Science ®Google Scholar
• The Special Study Group of the Progressive Renal Dysfunction Research Group of the Ministry of Health Labor and Welfare. Evidence-Based Clinical Practice Guidelines for IgA Nephropathy 2017. Tokyo-igakusha, Tokyo; 2017.
   Google Scholar
• Vieira SM, Pagovich OE, Kriegel MA. Diet, microbiota, and autoimmune diseases. Lupus. 2014;23:518–526. doi:10.1177/096120331350140124763536
   PubMed Web of Science ®Google Scholar
• Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med. 1998;338(17):1202–1211. doi:10.1056/NEJM1998042333817079554862
   PubMed Web of Science ®Google Scholar
• Vega GL, Toto RD, Grundy SM. Metabolism of low-density lipoproteins in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia. Kidney Int. 1995;47:579–586. doi:10.1038/ki.1995.737723244
   PubMed Web of Science ®Google Scholar
• Chan MK, Persaud JW, Ramdial L, Varghese Z, Sweny P, Moorhead JF. Hyperlipidemia in untreated nephrotic syndrome, increased production, or decreased removal? Clin Chim Acta. 1981;117:317–323. doi:10.1016/0009-8981(81)90119-47318185
   PubMed Web of Science ®Google Scholar
• Scarpioni R, Ricardi M, Albertazzi V, Melfa L. Treatment of dyslipidemia in chronic kidney disease: effectiveness and safety of statins. World J Nephrol. 2012;1:184–194. doi:10.5527/wjn.v1.i6.18424175258
   PubMedGoogle Scholar
• Hager MR, Narla AD, Tannock LR. Dyslipidemia in patients with chronic kidney disease. Rev Endocrine Metabol Disord. 2016;18:29–40. doi:10.1007/s11154-016-9402-z
   Web of Science ®Google Scholar
• Tsimihodimos V, Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol. 2008;28:958–973. doi:10.1159/00014402418612199
   PubMed Web of Science ®Google Scholar
• Kaseda R, Jabs K, Hunley TE, et al. Dysfunctional high-density lipoproteins in children with chronic kidney disease. Metabolism. 2015;64:263–273. doi:10.1016/j.metabol.2014.10.02025467845
   PubMed Web of Science ®Google Scholar
• Shoji T, Abe T, Matsuo H, et al. Chronic kidney disease, dyslipidemia, and atherosclerosis. J Atheroscler Thromb. 2012;19:299–315. doi:10.5551/jat.1045422166970
   PubMed Web of Science ®Google Scholar
• McGill HC Jr, McMahan CA, Herderick EE, Malcom GT, Tracy RE, Strong JP. Origin of atherosclerosis in childhood and adolescence. Am J Clin Nutr. 2000;72(Suppl):1307S–1315S. doi:10.1093/ajcn/72.5.1307s11063473
   PubMed Web of Science ®Google Scholar
• Scorletti E, Byrne CD. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev Nutr. 2013;33(1):231–248. doi:10.1146/annurev-nutr-071812-16123023862644
   PubMed Web of Science ®Google Scholar
• Rizos EC, Elisaf MS. Does supplementation with omega-3 PUFAs add to the prevention of cardiovascular disease? Curr Cardiol Rep. 2017;19(6):47. doi:10.1007/s11886-017-0856-828432658
   PubMed Web of Science ®Google Scholar
• Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308(10):1024–1033. doi:10.1001/2012.jama.1137422968891
   PubMed Web of Science ®Google Scholar
• Donadio JV Jr. An overview of ω-3 fatty acids in clinical renal diseases In: De Caterina R, Endres S, Kristensen SD, Schmidt EB, editors. Current Topics in Cardiovascular Disease. 1st ed. Verona, Italy: Bi & Gi Publishers; 1993:123–132.
   Google Scholar
• Hogg RJ, Waldo B. Advances in treatment: immunoglobulin A nephropathy. Semin Nephrol. 1996;16:511–516.9125795
   PubMed Web of Science ®Google Scholar
• Donadio JV Jr, Bergstralh EJ, Offord KP, Spencer DC, Holley KE. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med. 1994;331:1194–1199. doi:10.1056/NEJM1994110333118047935657
   PubMed Web of Science ®Google Scholar
• Donadio JV Jr, Grande JP, Bergstralh EJ, et al. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol. 1999;10:1772–1777.10446945
   PubMed Web of Science ®Google Scholar
• Barcelli UO, Miyata J, Ito Y, et al. Beneficial effects of polyunsaturated fatty acids in partially nephrectomized rats. Prostaglandins. 1986;32:211–219. doi:10.1016/0090-6980(86)90126-73797690
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Wheeler DC, Sandstrom DJ, Kawachi H, Salant DJ. Fish oil ameliorates renal injury and hyperlipidemia in the Milan normotensive rat model of focal glomerulosclerosis. J Am Soc Nephrol. 1995;6:1468–1475.8589325
   PubMed Web of Science ®Google Scholar
• Rahman MA, Sauter DC, Young MR. Effects of dietary fish oil on the induction of experimental membranous nephropathy in the rat. Lab Invest. 1991;64:371–376.1706005
   PubMed Web of Science ®Google Scholar
• Raina R, Krishnappa V. An update on LDL apheresis for nephrotic syndrome. Pediatr Nephrol. 2019;34:1655. doi:10.1007/s00467-018-4061-930218191
   PubMed Web of Science ®Google Scholar
• Shah L, Hooper DK, Okamura D, et al. LDL-apheresis-induced remission of focal segmental glomerulosclerosis recurrence in pediatric renal transplant recipients. Pediatr Nephrol. 2019;34:2343. doi:10.1007/s00467-019-0426-631250206
   PubMed Web of Science ®Google Scholar
• Donadio JV Jr, Grande JP. IgA nephropathy. N Engl J Med. 2002;347:738–748. doi:10.1056/NEJMra02010912213946
   PubMed Web of Science ®Google Scholar
• Li K, Huang T, Zheng J, Wu K, Li D. Effect of murine-derived ω-3 polyunsaturated fatty acids on C-reactive protein, interleukin 6, and tumor necrosis factor α: a meta-analysis. PLoS One. 2014;9(2):e88103. doi:10.1371/journal.pone.008810324505395
   PubMed Web of Science ®Google Scholar
• Borges MC, Santos FM, Telles RW, Correia MI, Lanna CC. Polyunsaturated omega-3 fatty acids and systemic lupus erythematosus: what do we know? Rev Bras Reumatol. 2014;54:459–466. doi:10.1016/j.rbr.2013.12.00225445629
   PubMedGoogle Scholar
• Halade GV, Rahman MM, Bhattacharya A, Barnes JL, Chandrasekar B, Fernandes G. Docosahexaenoic acid-enriched fish oil attenuates kidney disease and prolongs acid-enriched fish oil attenuates kidney disease and prolongs the median and maximal life span of autoimmune lupus-prone mice. J Immunol. 2010;184:5280–5286. doi:10.4049/jimmunol.090328220368275
   PubMed Web of Science ®Google Scholar
• Wu L, Parhofer KG. Diabetic dyslipidemia. Metabolism. 2014;63(12):1469–1479. doi:10.1016/j.metabol.2014.08.01025242435
   PubMed Web of Science ®Google Scholar
• Weintraub HS. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. Postgrad Med. 2014;126(7):7–18. doi:10.3810/pgm.2014.11.2828
   PubMed Web of Science ®Google Scholar
• Constantin MM, Nita JE, Olteanu R, et al. Significance and impact of dietary factors on systemic lupus erythematosus pathogenesis (Review). Exp Ther Med. 2019;17:1085–1090. doi:10.3892/etm.2018.698630679978
   PubMed Web of Science ®Google Scholar
• Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia-A Science Advisory from the American Heart Association. Circulation. 2019;140:e673–e691. doi:10.1161/CIR.000000000000070931422671
   PubMed Web of Science ®Google Scholar
• Grande JP, Walker HJ, Holub BJ, et al. Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo. Kidney Int. 2000;57:1027–1040. doi:10.1046/j.1523-1755.2000.00930.x10720955
   PubMed Web of Science ®Google Scholar
• Dong W, Sell JE, Pestka JJ. Quantitative assessment of mesangial immunoglobulin A (IgA) accumulation, elevated circulating IgA immune complexes, and hematuria during vomitoxin-induced IgA nephropathy. Fundam Appl Toxicol. 1991;17:197–207. doi:10.1016/0272-0590(91)90251-X1833256
   PubMedGoogle Scholar
• Pestka JJ, Zhou HR. Interleukin-6-deficient mice refractory to IgA dysregulation but not anorexia induction by vomitoxin (deoxynivalenol) ingestion. Food Chem Toxicol. 2000;38:565–575. doi:10.1016/S0278-6915(00)00041-710942317
   PubMed Web of Science ®Google Scholar
• Hamazaki T, Tateno S, Shishido H. Eicosapentaenoic acid, and IgA nephropathy. Lancet. 1984;1:11017–11018. doi:10.1016/S0140-6736(84)92355-9
   Web of Science ®Google Scholar
• Alexopoulos E, Stangou M, Pantzaki A, Kirmizis D, Memmos D. Treatment of severe IgA nephropathy with omega-3 fatty acids: the effect of a “very low dose” regimen. Ren Fail. 2004;26:453–459. doi:10.1081/JDI-20002676315462115
   PubMed Web of Science ®Google Scholar
• Sulikowsa B, Niewegłowski T, Manitius J, Lysiak-Szydłowska W, Rutkowski B. Effect of 12-month therapy with omega-3 polyunsaturated acids on glomerular filtration response to dopamine in IgA nephropathy. Am J Nephrol. 2004;24:474–482. doi:10.1159/00008067015340256
   PubMed Web of Science ®Google Scholar
• Donadio JV Jr, Larson TS, Bergstralh EJ, Grande JP. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol. 2001;12:791–799.11274240
   PubMed Web of Science ®Google Scholar
• Ferraro PM, Ferraccioli GF, Gambaro G, Fulignati P, Costanzi S. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. Nephrol Dial Transplant. 2009;24:156–160. doi:10.1093/ndt/gfn45418685141
   PubMed Web of Science ®Google Scholar
• Bennett WM, Walker RG, Kincaid-Smith P. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trial. Clin Nephrol. 1989;31:128–131.2539929
   PubMed Web of Science ®Google Scholar
• Pettersson EE, Rekola S, Berglund L, et al. Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study. Clin Nephrol. 1994;41:183–190.8026109
   PubMed Web of Science ®Google Scholar
• Hogg RJ, Lee J, Nardelli N, et al. Clinical trial to evaluate omega-3 fatty acids and alternate-day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol. 2006;1:467–474. doi:10.2215/CJN.0102090517699247
   PubMed Web of Science ®Google Scholar
• Omega-3 Fatty Acids for Proteinuria Due to Nephrotic Syndrome: A Review of Clinical Effectiveness and Cost-Effectiveness [Internet]. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health;2016 2 5 KEY FINDINGS Available from https://www.ncbi.nlm.nih.gov/books/NBK350634/. Accessed 217, 2020.
   Google Scholar
• Yuzawa Y, Yamamoto R, Takahashi K, et al. Evidence-based clinical practice guidelines for IgA nephropathy 2014. Clin Exp Nephrol. 2016;20:511–535. doi:10.1007/s10157-015-1223-y27095365
   PubMed Web of Science ®Google Scholar
• Chou HH, Chiou YY, Hung PH, Chiang PC, Wang ST. Omega-3 fatty acids ameliorate proteinuria but not renal function in IgA nephropathy: a meta-analysis of randomized controlled trials. Nephron Clin Pract. 2012;121(1–2):c30–5. doi:10.1159/00034192923095320
   PubMedGoogle Scholar
• Reid S, Cawthon PM, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2011;16(3):CD003962. doi:10.1002/14651858.cd003962.pub2
   Web of Science ®Google Scholar
• Miller ER III, Juraschek SP, Appel LJ, et al. The effect of n-3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: a meta-analysis of clinical trials. Am J Clin Nutr. 2009;89(6):1937–1945. doi:10.3945/ajcn.2008.2686719403630
   PubMed Web of Science ®Google Scholar
• Colquitt JL, Kirby J, Green C, Cooper K, Trompeter RS. The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review. Health Technol Assess. 2007;11(21):iii–x.
   Web of Science ®Google Scholar